A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

ClinicalTrials.gov ID

NCT07202546

Lead Sponsor

ViiV HealthcareINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

186Estimated

Last Update Posted

Jul 23, 2026Actual

Start Date

Feb 11, 2026Actual

Primary Completion Date

Jun 11, 2027Estimated

Completion Date

May 22, 2028Estimated

Official Title

A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (INNOVATE Study)

Brief Summary

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.

• HIV Infections

• VH4524184
• Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets
• Dolutegravir / Lamivudine (DTG/3TC)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Participant must be at least 18 years of age (or older, if required for adults by local regulations) at the time of signing the informed consent.

2. Screening CD4+ T-cell count >200 cells/microlitre (µL).

3. Documented HIV-1 infection and Screening plasma HIV-1 RNA of ≥1000 copies/millilitre (mL). A single repeat of this test is allowed within a single Screening period to determine eligibility.

4. Treatment-naive: Defined as no ARVs (in combination or monotherapy) received after the diagnosis of HIV-1 infection.

5. Body weight >=50.0 kilogram (kg) [(110 pounds (lbs)] for participants assigned male at birth and >=45.0 kg (99 lbs) for participants assigned female at birth. BMI within the range 18.5-35.5 kg/m^2 (inclusive - applies to males and females).

6. There are no contraceptive requirements for participants assigned male at birth.

7. Participants assigned female at birth are eligible to participate if they are not pregnant or breastfeeding and one of the following conditions applies:

   • Is a Participant of non-childbearing potential (PONCBP);OR Is a Participant of childbearing potential (POCBP) and using a contraceptive method with a failure rate of less than (<) 1% prior to and during the study intervention period, and for at least 1 week after the last dose of VH4524184 plus FTC/TAF FDC, or through the end of study (if in the control arm and never received VH4524184).
   • A POCBP must have a negative pregnancy test at Screening (serum) and on Day 1 (urine) before the first dose of study intervention.
   • If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. Participant with a positive serum test must be excluded.

8. Capable of giving signed informed consent. Persons who are placed in an institution by order of a public authority or a court are excluded from participation in this study.

Exclusion Criteria:

1. Participants who are breastfeeding or plan to breastfeed during the study.
2. Participants with acute HIV infection, evidenced by acute retroviral syndrome (e.g., fever, malaise, fatigue, etc.) and/or evidence of recent (within 3 months) documented viremia without antibody production and/or evidence of recent (within 3 months) documented seroconversion.
3. Any evidence of an active Centres for Disease Control and Prevention (CDC) Stage 3 disease [CDC 2014], except cutaneous Kaposi's sarcoma not requiring systemic therapy during the study. Historical CD4+ cell counts less than 200 cells/µL are not exclusionary.
4. Unstable liver disease known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
5. History of cirrhosis with or without viral hepatitis co-infection.
6. Participants with HCV co-infection will be excluded from the study.
7. Individuals who are co-infected with HIV and HBV will be excluded Participants diagnosed with syphilis at Screening (i.e., positive syphilis testing) should be treated as per local guidelines and will be eligible to enroll at any time regardless of the stage of disease.
8. Uncontrolled malignancy is excluded, whereas participants who have controlled malignancies may be included in agreement between the investigator and the ViiV Healthcare medical monitor.
9. Any pre-existing physical, or mental condition (including alcohol or drug abuse) which, in the opinion of the investigator (with or without psychiatric evaluation) or the ViiV Healthcare medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
10. Any condition which, in the opinion of the investigator or the ViiV Healthcare medical monitor, that may interfere with the absorption, distribution, metabolism or excretion of the study interventions or render the participant unable to take oral medication and normal gastrointestinal anatomy or motility or hepatic and/or renal function
11. Clinically significant CV disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty or any clinically significant cardiac disease.
12. Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
13. History of sensitivity to any of the study medications, or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or ViiV Healthcare medical monitor, contraindicates their participation.
14. Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (≤325 mg) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
15. Treatment with any of the following agents within 60 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any systemic immune suppressant.
16. Treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity (such as hydroxyurea or foscarnet) within 30 days of Day 1.
17. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
18. Exposure to an approved vaccine within 14 days prior to Day 1.
19. Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research
20. Participants with known or suspected presence of virologic resistance mutations as defined by the Stanford HIV Drug Resistance Database to INSTIs or NRTIs. This determination will be based on local virologic resistance testing, either at Screening or within the 3 months prior to Screening. ViiV Healthcare clinical virologist and/or ViiV Healthcare medical monitor will verify eligibility to this criterion prior to Day 1.
21. Creatinine clearance (eGFR) of <60 mL/min/1.73 m2 via CKD-EPI race neutral method [Delgado, 2021].
22. ALT >3 times the upper limit of normal (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.
23. Any Grade 4 laboratory abnormality at screening, except for a Grade 4 CPK and lipid abnormalities (e.g., total cholesterol, triglycerides, etc.) will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the ViiV Healthcare medical monitor. A single repeat of any lab abnormality is allowed within a single screening period to determine eligibility.
24. Any acute laboratory abnormality at screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
25. Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination and will be the screening ECG entered into the eCRF): QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 msec (males) or >470 msec (females); >480 msec for participants with bundle branch block.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

ViiV HealthcareINDUSTRY

• Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579

  CompletedInterventionalPhase 2Updated Sep 30, 2025
• A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)

  NCT07816250

  Not yet recruitingInterventionalPhase 2Updated Sep 11, 2026
• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

  NCT06214052

  CompletedInterventionalPhase 2Updated Jun 29, 2025
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

  NCT05979311

  Active, not recruitingInterventionalPhase 3Updated Jul 2, 2026
• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

  NCT05917509

  CompletedInterventionalPhase 3Updated May 27, 2026
• A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

  NCT06061081

  TerminatedInterventionalPhase 2Updated Oct 20, 2025

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718